Marizyme
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1645 Palm Beach Lakes Blvd Ste 1200, Wes...Phone Number
(561) 320-3929Website
www.marizyme.comRevenue
<$5 MillionStock Symbol
MRZMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Marizyme
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease based therapeutic Krillase® platform.Explore more
Marizyme Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Marizyme your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Marizyme launches new products
Click to see if Marizyme had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Marizyme has new funding data
Check if Marizyme has recently received funding, and reach out quickly before it becomes old news!
Marizyme, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Marizyme recently announced quarterly report
Check out if Marizyme is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Marizyme
Recommended Actions
Find VP level buyers at Marizyme
Find 3 more new buyers
Compare Similar Companies to Marizyme
Compare insights from companies similar to Marizyme, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Marizyme is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Marizyme is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Marizyme.
Marizyme Tech Stack
A closer look at the technologies used by Marizyme
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Partnership
Partnership, Product Development, Research & Development
Open Position
Project
Funding
Facilities Relocation / Expansion
Real Estate
Marizyme News & Media
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated development and commercialization of medical technologies that improve patient health outcomes, announced today that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company’s intellectual property.Marizyme CEO Delivers Business Update
JUPITER, FL, May 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel.Marizyme Inc. Letter to Shareholders
Marizyme Inc. - A Letter to our Shareholders Marizyme Inc. (OTCQB:MRZM) JUPITER, FLORIDA, UNITED STATES OF AMERICA, April 5, 2022 /EINPresswire.com/ -- To Our Valued Marizyme Shareholders, This is our first Quarterly Shareholder Update since our …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Marizyme
Sign Up For FreeTo access detailed company insights
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outc... Read More
